医药板块本周大涨，关注恒生创新药ETF（159316）、医药ETF（512010）等投资价值

Core Insights - The Hang Seng Hong Kong Stock Connect Innovation Drug Index increased by 7.1% this week, while the CSI Hong Kong Stock Connect Medical and Health Comprehensive Index rose by 6.9% [1] - The CSI Innovation Drug Industry Index and the CSI Biotechnology Theme Index saw increases of 5.3% and 3.6%, respectively, with the CSI 300 Medical and Health Index up by 3.4% [1] - The Hang Seng Innovation Drug ETF (159316) experienced a net inflow of nearly 200 million yuan this week, bringing its total size to over 2 billion yuan, a record high [1] Index Performance - Weekly performance: - Hang Seng Innovation Drug Index: +7.1% - CSI Hong Kong Stock Connect Medical and Health Comprehensive Index: +6.9% - CSI Innovation Drug Industry Index: +5.3% - CSI Biotechnology Theme Index: +3.6% - CSI 300 Medical and Health Index: +3.4% [3] - Year-to-date performance: - Hang Seng Innovation Drug Index: +116.2% - CSI Hong Kong Stock Connect Medical and Health Comprehensive Index: +102.9% - CSI Innovation Drug Industry Index: +43.5% - CSI Biotechnology Theme Index: +31.2% - CSI 300 Medical and Health Index: +22.9% [7] Valuation Metrics - Current rolling P/E ratios: - Hang Seng Innovation Drug Index: 57.7x - CSI Hong Kong Stock Connect Medical and Health Comprehensive Index: 30.7x - CSI Innovation Drug Industry Index: 57.3x - CSI Biotechnology Theme Index: 62.3x - CSI 300 Medical and Health Index: 33.0x [3] - Valuation percentile as of July 2023: - Hang Seng Innovation Drug Index: 48.5% - CSI Hong Kong Stock Connect Medical and Health Comprehensive Index: 88.1% - CSI Innovation Drug Industry Index: 82.1% - CSI Biotechnology Theme Index: 60.2% [3] ETF Overview - The Hang Seng Innovation Drug Index has one ETF tracking it, while the CSI Hong Kong Stock Connect Medical and Health Comprehensive Index has four ETFs [5] - The CSI Innovation Drug Industry Index is tracked by seven ETFs, and the CSI Biotechnology Theme Index has four ETFs [5]